Title | A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) |
Protocole ID | CA055-026 |
ClinicalTrials.gov ID | NCT05469737 |
Cancer Type(s) | Myelodysplastic Syndrome |
Phase | Phase II-III |
Stage | |
Study Type | Clinical |
Drug | Azacitidine orale |
Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1 |
City | |
Principal Investigator |
Dr. John Storring |
Coordinator |
Judit Kokai 438-888-1582 |
Status | Recruiting |
Activation Date | 12-04-2023 |
Eligibility Criteria |
|
Exclusion Criteria |
|